Advertisement
RVTY vs WAT
Which Stock Would AI Choose? Revvity (RVTY) vs. Waters Corporation (WAT) Stock Comparison
Key Takeaways
- Revvity (RVTY) and Waters Corporation (WAT) are both life sciences tools companies, but they serve meaningfully different customer bases and growth profiles.
- Revvity is reshaping its portfolio through the planned divestiture of its China Immunodiagnostics business, while Waters is integrating its large acquisition of BD Biosciences and Diagnostic Solutions.
- Waters commands a much larger market capitalization and higher revenue base, but recent margin compression tied to deal integration contrasts with Revvity's steadier, lower-growth profile.
- Both stocks have experienced volatility around earnings, with sentiment driven by margin outlooks and acquisition-related execution rather than top-line results alone.
- Relative performance has diverged, with Waters showing stronger long-term share appreciation and Revvity trading with a more moderate valuation.
Introduction
Investors evaluating the life sciences and laboratory tools sector often compare RVTY and WAT because both supply critical instrumentation and consumables to pharmaceutical, biotech, and academic customers, yet they approach the market from different angles. This stock comparison is relevant for traders and long-term investors seeking to understand relative performance, market positioning, and risk exposure across two names responding to distinct catalysts. Where Revvity is streamlining toward higher-growth diagnostics and software, Waters is scaling through a transformative acquisition. Examining their recent momentum, business models, and sentiment helps clarify which profile may better fit current market conditions.
RVTY Overview and Recent Performance
Revvity, Inc. is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. It operates through two segments—Life Sciences, providing reagents, instruments, and software for biopharma and academic research, and Diagnostics, focused on immunodiagnostics and reproductive health. The company generates roughly $2.9 billion in annual revenue and is a member of the S&P 500 index.
In recent market activity, Revvity's shares have been under pressure despite solid operational results. Its first-quarter results showed adjusted earnings per share (EPS) of $1.06, up 5% year over year, with revenue rising 7% to approximately $711 million and organic growth of about 3%. However, adjusted operating margin declined roughly 200 basis points, reflecting ongoing investments and product mix. A key development has been the decision to divest its China Immunodiagnostics business, which represented about 6% of 2025 revenue, with a definitive agreement expected later in 2026. Management also repurchased more than $800 million of stock in 2025, signaling confidence in its transformation.
WAT Overview and Recent Performance
Waters Corporation, founded in 1958, develops and manufactures analytical instruments, software, and consumables for liquid chromatography, mass spectrometry, and thermal analysis used in scientific research and quality testing. It operates across pharmaceutical, industrial, and governmental and academic end markets, with a larger revenue base than Revvity and a market capitalization near $30 billion.
Waters has been in the early-to-middle stages of a long-running instrument replacement cycle while simultaneously integrating its acquisition of BD Biosciences and Diagnostic Solutions. Recent quarters showed strong reported revenue growth—up about 7% in its latest fourth quarter—driven by recurring chemistry and service revenue. Yet the integration has introduced headwinds, including softer demand in China, delayed export approvals, and near-term margin compression as the company absorbs acquisition costs. Full-year guidance calls for combined-company sales of roughly $6.4 billion and adjusted EPS near the mid-$14 range, with management pointing to meaningful cost and revenue synergies ahead.
Trending AI Robots
For traders seeking an automated edge, Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this trending section. Each bot operates with its own trading style, strategy, timeframe, performance track record, statistics, and set of tickers it trades. Many of these bots showcase measurable metrics—such as win rates, profit factors, and historical trade counts—that allow traders to evaluate suitability at a glance. Explore the Trending AI Robots to see which strategies are currently aligned with the market.
Head-to-Head Comparison
The two companies differ most sharply in scale, strategy, and risk profile. Waters is a larger, more diversified instrument maker whose recent growth is tied to a major acquisition and a multi-year replacement cycle, giving it greater top-line expansion potential but also elevated integration risk and a richer valuation. Revvity is smaller and more focused on diagnostics and software, offering a steadier but lower-growth trajectory, with its China divestiture aimed at improving long-term margins and reducing geopolitical exposure.
On momentum, Waters has shown stronger recent share appreciation, reflecting optimism around its combined-company outlook and recurring-revenue acceleration. Revvity, by contrast, has lagged as investors weigh margin pressure and a conservative 2%–3% organic growth outlook. Both face common headwinds—pharmaceutical funding uncertainty, foreign exchange effects, and softer academic and government demand—but their divergent exposure to diagnostics, China, and mergers and acquisitions (M&A) shapes distinct risk-reward trade-offs. Sentiment toward Waters leans on execution of synergies, while sentiment toward Revvity hinges on margin recovery and portfolio optimization.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative positioning, and catalyst clarity, Tickeron's AI would likely assign a slight preference to Waters Corporation. The stock's stronger recent momentum, larger scale, recurring-revenue growth, and clearer multi-year growth narrative from its instrument replacement cycle and acquisition synergies present a more defined trend path. However, Waters' elevated valuation and integration-related margin volatility temper confidence, while Revvity's steadier cash generation and shareholder returns offer a more defensive profile. The verdict therefore favors Waters with moderate conviction, while acknowledging that either name could outperform depending on how near-term execution and margin trajectories evolve.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVTY is a StrongBuy and WAT is a Hold.
Momentum Indicator for RVTY turns positive, indicating new upward trend
RVTY saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 64 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +1.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVTY advanced for three days, in 199 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 110 of 181 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for RVTY moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 23 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for RVTY turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 39 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
RVTY broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.451) is normal, around the industry mean (66.137). P/E Ratio (76.332) is within average values for comparable stocks, (2.464). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (3.473). Dividend Yield (0.002) settles around the average of (0.002) among similar stocks. P/S Ratio (5.656) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
WAT's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for WAT moved out of overbought territory on September 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 23 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
WAT broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on WAT as a result. In 60 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for WAT just turned positive on October 21, 2026. Looking at past instances where WAT's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Following a +5.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 175 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 118 of 207 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.933) is normal, around the industry mean (66.137). WAT has a moderately high P/E Ratio (113.987) as compared to the industry average of (2.464). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).
RVTY | WAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 67 | |
SMR RATING 1..100 | 86 | 89 | |
PRICE GROWTH RATING 1..100 | 3 | 9 | |
P/E GROWTH RATING 1..100 | 6 | 2 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RVTY's Valuation (79) in the Medical Specialties industry is in the same range as WAT (90). This means that RVTY’s stock grew similarly to WAT’s over the last 12 months.
WAT's Profit vs Risk Rating (67) in the Medical Specialties industry is somewhat better than the same rating for RVTY (100). This means that WAT’s stock grew somewhat faster than RVTY’s over the last 12 months.
RVTY's SMR Rating (86) in the Medical Specialties industry is in the same range as WAT (89). This means that RVTY’s stock grew similarly to WAT’s over the last 12 months.
RVTY's Price Growth Rating (3) in the Medical Specialties industry is in the same range as WAT (9). This means that RVTY’s stock grew similarly to WAT’s over the last 12 months.
WAT's P/E Growth Rating (2) in the Medical Specialties industry is in the same range as RVTY (6). This means that WAT’s stock grew similarly to RVTY’s over the last 12 months.
| RVTY | WAT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 72% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 72% | 2 days ago 65% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 69% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 65% | 2 days ago 64% |
| Advances ODDS (%) | 2 days ago 67% | 4 days ago 63% |
| Declines ODDS (%) | 6 days ago 67% | 2 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 73% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 57% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVTY’s FA Score shows that 2 FA rating(s) are green while WAT’s FA Score has 2 green FA rating(s).
- RVTY’s FA Score: 2 green, 3 red.
- WAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVTY’s TA Score shows that 3 TA indicator(s) are bullish while WAT’s TA Score has 4 bullish TA indicator(s).
- RVTY’s TA Score: 3 bullish, 5 bearish.
- WAT’s TA Score: 4 bullish, 4 bearish.
Price Growth
RVTY (@Medical Specialties) experienced а +4.06% price change this week, while WAT (@Medical Specialties) price change was +3.83% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.55%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
Reported Earning Dates
RVTY is expected to report earnings on Nov 03, 2026.
WAT is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical Specialties (+1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
RVTY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with TMO. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | +0.94% | ||
| TMO - RVTY | 69% Closely correlated | -0.40% | ||
| AZTA - RVTY | 63% Loosely correlated | +1.36% | ||
| A - RVTY | 62% Loosely correlated | -0.47% | ||
| CRL - RVTY | 62% Loosely correlated | +1.68% | ||
| BIO - RVTY | 60% Loosely correlated | +1.77% | ||
More | ||||
WAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, WAT has been loosely correlated with A. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | -0.42% | ||
| A - WAT | 65% Loosely correlated | -0.47% | ||
| RVTY - WAT | 60% Loosely correlated | +0.94% | ||
| BRKR - WAT | 58% Loosely correlated | +0.49% | ||
| CRL - WAT | 57% Loosely correlated | +1.68% | ||
| TMO - WAT | 57% Loosely correlated | -0.40% | ||
More | ||||